0.0001 0 (0%) | 02-05 15:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 0 | 1-year : | 0 |
Resists | First : | 0 | Second : | 0 |
Pivot price | 0 | |||
Supports | First : | 0 | Second : | 0 |
MAs | MA(5) : | 0 | MA(20) : | 0 |
MA(100) : | 0 ![]() |
MA(250) : | 0.47 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 0 | D(3) : | 1 |
RSI | RSI(14): 3.7 | |||
52-week | High : | 1.38 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ELOX ] has closed above bottom band by 50.0%. Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0 - 0 | 0 - 0 |
Low: | 0 - 0 | 0 - 0 |
Close: | 0 - 0 | 0 - 0 |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Tue, 12 Nov 2024
Eloxx Pharmaceuticals Announces Key Corporate Accomplishments - GlobeNewswire
Thu, 17 Oct 2024
Eloxx Pharmaceuticals enacts option repricing for CEO - Investing.com
Thu, 11 Jul 2024
Eloxx Pharmaceuticals Provides Pipeline and Financing Updates - GlobeNewswire
Tue, 16 Apr 2024
Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates - GlobeNewswire
Tue, 16 May 2023
Why Is Eloxx Pharmaceuticals (ELOX) Stock Down 27% Today? - InvestorPlace
Wed, 30 Mar 2022
Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 3 (M) |
Shares Float | 3 (M) |
Held by Insiders | 0.4 (%) |
Held by Institutions | 19.5 (%) |
Shares Short | 21 (K) |
Shares Short P.Month | 34 (K) |
EPS | -8.89 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | -6.54 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -73.3 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -6.13 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -18 (M) |
Levered Free Cash Flow | -8 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | -0.01 |
Price to Sales | 0 |
Price to Cash Flow | -0.01 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |